Loading
A phase 3 trial of Capecitabine and Lapatinib in advanced solid tumours, run by Tianjin Hemay Pharmaceutical Co., Ltd, now recruiting.
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer is a phase 3 interventional study registered as NCT06313983 by Tianjin Hemay Pharmaceutical Co., Ltd, with 339 participants planned, started 2022-01-08 and due to reach its primary completion in 2025-12. Interventions recorded: Hemay022+AI and Lapatinib+Capecitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/